Research programme: diabetic foot ulcer therapy - PLIVAAlternative Names: Diabetic foot ulcer therapy research programme - PLIVA; PLR-15
Latest Information Update: 16 Aug 2007
At a glance
- Originator PLIVA d.d.
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Diabetic foot ulcer
Most Recent Events
- 20 Jul 2005 Preclinical trials in Diabetic foot ulcer in Europe (unspecified route)